Minzasolmin

Minzasolmin
Names
	IUPAC name N-[(2R)-1-(1H-indol-3-yl)hexan-2-yl]-2-(4-methylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
Identifiers
CAS Number	1802518-92-8;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL5095072;
ChemSpider	115010423;
KEGG	D12796;
PubChem CID	118279413;
UNII	3N0435TG2D;
	InChI InChI=1S/C23H31N5OS/c1-3-4-7-18(14-17-15-24-20-9-6-5-8-19(17)20)26-22(29)21-16-25-23(30-21)28-12-10-27(2)11-13-28/h5-6,8-9,15-16,18,24H,3-4,7,10-14H2,1-2H3,(H,26,29)/t18-/m1/s1 Key: GDFWCSZNQVAQGR-GOSISDBHSA-N;
	SMILES CCCC[C@H](CC1=CNC2=CC=CC=C21)NC(=O)C3=CN=C(S3)N4CCN(CC4)C;
Properties
Chemical formula	C23H31N5OS
Molar mass	425.60 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Minzasolmin (development names DLX313 and UCB0599) is an experimental small-molecule drug developed for Parkinson's disease that is designed to prevent misfolding of α-synuclein.^[1]^[2]

References edit

^ Schwarz, Thomas C.; Beier, Andreas; Ledolter, Karin; Gossenreiter, Thomas; Höfurthner, Theresa; Hartl, Markus; Baker, Terry S.; Taylor, Richard J.; Konrat, Robert (11 April 2023). "High-resolution structural information of membrane-bound α-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599". Proceedings of the National Academy of Sciences. 120 (15): e2201910120. Bibcode:2023PNAS..12001910S. doi:10.1073/pnas.2201910120. PMC 10104497. PMID 37027427. S2CID 258007748.
^ Price, Diana L.; Khan, Asma; Angers, Rachel; Cardenas, Alvaro; Prato, Maria Key; Bani, Massimo; Bonhaus, Douglas W.; Citron, Martin; Biere, Anja-Leona (17 July 2023). "In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease". npj Parkinson's Disease. 9 (1): 114. doi:10.1038/s41531-023-00552-7. ISSN 2373-8057. PMC 10352257. PMID 37460603.